• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Bioinformatics Analysis Identifies Ten Key Hub Genes in Gestational Diabetes

by
November 16, 2026
in Health
Reading Time: 6 mins read
0
Bioinformatics Analysis Identifies Ten Key Hub Genes in Gestational Diabetes

Bioinformatics Analysis Identifies Ten Key Hub Genes in Gestational Diabetes

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A computational bioinformatics investigation analyzing umbilical cord blood next-generation sequencing data has identified 953 differentially expressed genes and ten central hub genes associated with gestational diabetes mellitus. The study, conducted by a research team including Varun Alur, Basavaraj Vastrad, Varshita Raju, Chanabasayya Vastrad, and Shivakumar Kotturshetti, utilized publicly deposited high-throughput RNA sequencing records to uncover candidate molecular markers and underlying biological pathways that distinguish gestational diabetes pregnancies from healthy control pregnancies. Gestational diabetes mellitus represents a widespread metabolic disorder arising during pregnancy, and identifying its specific molecular signatures provides essential clues for understanding disease pathology, tracking prognosis, and pinpointing candidates for targeted therapy.

To explore the molecular regulatory networks driving gestational diabetes, the investigators obtained the next-generation sequencing dataset GSE154377 from the Gene Expression Omnibus repository. The dataset was generated using the GPL20301 Illumina HiSeq 4000 platform and comprised transcriptomic profiles from umbilical cord blood, comparing 33 samples from pregnancies diagnosed with gestational diabetes mellitus against 28 normal pregnancy control samples. Differential gene expression was resolved using the DESeq2 package within the R Bioconductor software environment. Transcripts meeting statistical thresholds of an adjusted P-value under 0.05, combined with an absolute log2 fold-change greater than 1.73 for upregulation and an absolute log2 fold-change greater than -0.69 for downregulation, were classified as significant differentially expressed genes.

The differential expression pipeline categorized a total of 953 genes, divided almost evenly into 478 upregulated transcripts and 475 downregulated transcripts. To characterize the biological functions and signaling pathways tied to these altered transcripts, the researchers carried out comprehensive functional enrichment profiling using the g:Profiler online tool to interrogate Gene Ontology terms and the REACTOME pathway database. Statistically significant enrichment was established at an adjusted P-value threshold below 0.05, allowing the team to separate the primary biological consequences of upregulated and downregulated molecular pathways in gestational diabetes tissue.

Enrichment analysis across Gene Ontology categories demonstrated that the identified genes participate in distinct structural and metabolic roles. In the biological process domain, differentially expressed genes showed significant enrichment in multicellular organismal processes, developmental processes, immune system processes, and cell activation. In the cellular component classification, altered transcripts mapped predominantly to the cell periphery, cellular membranes, the endomembrane system, and the cytoplasm. Regarding molecular function, significant terms encompassed transporter activity, channel activity, enzyme binding, and general protein binding. Upregulated genes exhibited targeted biological process enrichment in multicellular organismal activity, whereas downregulated genes demonstrated pronounced enrichment in cell activation programs.

Pathway mapping using the REACTOME database further elucidated distinct signaling profiles between the two expression groups. Upregulated genes were predominantly enriched in pathways governing the formation of the cornified envelope as well as cell-cell junction organization. In contrast, downregulated transcripts were enriched primarily in hemostasis pathways, cell activation cascades, and cellular responses to elevated platelet cytosolic calcium ion flux. These pathway enrichments indicate that altered hemostatic regulation, structural cell-to-cell contact modifications, and immunological signaling mechanisms operate concurrently within the fetal-placental circulation during gestational diabetes.

To map protein-level relationships, the investigators submitted the differentially expressed genes to the Integrated Interactions Database interactome, constructing a comprehensive protein-protein interaction network visualized in Cytoscape version 3.8.2. The complete interaction network incorporated 8,472 nodes interconnected by 20,624 edges. Topological metrics—including node degree, betweenness centrality, stress centrality, and closeness centrality—were quantified using Cytoscape’s NetworkAnalyzer plugin to identify the most critical hub genes. This topological screening prioritized ten essential hub genes: TRIM54, ELAVL2, PTN, KIT, BMPR1B, APP, SRC, ITGA4, RPA1, and ACTB. Subnetwork clustering via the PEWCC1 plugin isolated two key functional modules: Module 1, containing 95 nodes and 103 edges tied to multicellular organismal processes and intrinsic membrane components, and Module 2, containing 79 nodes and 131 edges associated with hemostasis, immune signaling, and enzyme binding.

To decipher upstream post-transcriptional control, the researchers constructed a microRNA-hub gene regulatory network using the miRNet database across fourteen predictive algorithms. Visualized in Cytoscape, the resulting interaction network spanned 2,598 nodes—comprising 307 hub genes and 2,291 microRNAs—connected by 17,035 regulatory edges. Within this network, specific target genes exhibited dense regulatory convergence: SRRM2 was targeted by 250 microRNAs including hsa-mir-582-5p, CDKN1A was targeted by 187 microRNAs including hsa-mir-657, MYH9 was linked to 126 microRNAs including hsa-mir-1231, APP was targeted by 125 microRNAs including hsa-mir-509-3-5p, ACTB was linked to 122 microRNAs including hsa-mir-192-3p, ERRFI1 was targeted by 70 microRNAs including hsa-mir-198, CCNE1 was regulated by 50 microRNAs including hsa-mir-181b-5p, and ELAVL2 was targeted by 43 microRNAs including hsa-mir-766-3p.

In parallel, the team evaluated transcriptional regulation by querying the NetworkAnalyst database and the ChEA algorithm to build a transcription factor-hub gene regulatory network. This regulatory map assembled 503 nodes—consisting of 309 hub genes and 194 transcription factors—bound by 7,686 edges. Among the primary interactions identified, SMAD3 was targeted by 58 transcription factors including EP300, CDKN1A was targeted by 57 transcription factors including STAT3, ACTB was targeted by 56 transcription factors including HOXC9, PKM was regulated by 55 transcription factors including FOXP1, and MYH9 was targeted by 53 transcription factors including ATF3. Furthermore, ERRFI1 was targeted by 43 transcription factors including CREM, ELAVL2 was linked to 41 regulators including BMI1, KIT was regulated by 34 factors including DMRT1, and PPARGC1A was targeted by 27 transcription factors including FOXA2.

The potential clinical predictive performance of the ten core hub genes was quantitatively assessed through receiver operating characteristic curve analysis using the pROC package in R. Applying logistic regression modeling across feasible classification thresholds, the investigators determined the area under the curve for each individual hub gene. Every screened hub gene demonstrated strong diagnostic capability with an area under the curve exceeding the 0.90 threshold: PTN achieved an area under the curve of 0.948, SRC reached 0.946, ELAVL2 recorded 0.937, KIT showed 0.932, BMPR1B achieved 0.927, TRIM54 registered 0.925, APP recorded 0.923, ITGA4 demonstrated 0.921, ACTB reached 0.916, and RPA1 attained 0.907. These high metrics indicate that the expression levels of these ten transcripts effectively differentiate gestational diabetes cord blood samples from control samples in this dataset.

The authors contextualized these computational discoveries by noting that several enriched genes and hub nodes have established associations with metabolic and vascular disorders such as preeclampsia, hypertension, obesity, and cardiovascular diseases, reflecting the shared pathophysiological landscape of metabolic syndrome in pregnancy. However, the researchers emphasized crucial limitations of the work: the findings are derived entirely from in silico bioinformatics analysis and statistical modeling of public sequencing data. While the identified hub genes, microRNAs, and transcription factor circuits provide prioritized candidate biomarkers for gestational diabetes detection and therapeutic targeting, direct experimental investigations and clinical cohort studies remain necessary to validate their precise biological mechanisms and diagnostic utility in patients.

The investigators situated their computational analysis within the broader clinical context of gestational diabetes, noting that the condition is rising worldwide while its pathogenesis remains complex and poorly understood. Several recognized risk factors contribute to its emergence, including advanced maternal age, family history of diabetes, obesity, cigarette smoking, genetic factors, hypertension, type 2 diabetes, and cardiovascular diseases. Earlier research demonstrated that genes such as PVT1, IL-6, IL-10, TNF-α, CAPN10, ADCYAP1, and ABHD5 exhibit altered expression during the disease, operating alongside key regulatory cascades including the PI3K/AKT, AMPK, vitamin D, TLR4/NF-kappaB, and AGEs-RAGE signaling pathways. By deploying bioinformatics tools to evaluate cord blood sequencing profiles, the current study sought to characterize broader multi-gene regulatory networks rather than focusing solely on isolated individual markers.

Beyond the primary hub interactions, the regulatory network analyses delineated additional candidate nodes across transcriptional and post-transcriptional levels. Within the microRNA-hub gene network, ANTXR1 was identified as being targeted by 36 microRNAs including hsa-mir-624-5p, while ZBTB8A was targeted by 34 microRNAs including hsa-mir-10b-5p. In the complementary transcription factor regulatory map, ZBTB8A was regulated by 29 transcription factors including GATA4. Synthesizing these regulatory connections allowed the authors to isolate an expanded set of interconnected biomarkers, including ERRFI1, CCNE1, ELAVL2, ANTXR1, ZBTB8A, SRRM2, PKM, ACTB, and KIT, along with microRNAs such as hsa-mir-198, hsa-mir-181b-5p, hsa-mir-624-5p, hsa-mir-509-3-5p, and hsa-mir-192-3p, and transcription factors including DMRT1 and HOXC9.

The investigators also related their findings to prior research examining shared molecular features between gestational diabetes and interrelated cardiometabolic disorders. Prior studies highlighted by the authors demonstrated that altered expression of biomarkers such as PPARGC1A and hsa-mir-657 participates directly in the development and progression of gestational diabetes. In addition, several core genes identified in the current network have established roles across related conditions: BMPR1B, BMP7, and SMAD3 have previously served as diagnostic indicators in hypertension, while APP, BMP7, SMAD3, and USP22 have been linked to obesity. Furthermore, BMP7, CDKN1A, MDM4, and SMAD3 have been investigated as prognostic markers in diabetes mellitus, and CDKN1A has been implicated in preeclampsia. In addition to the primary ten hub genes, the authors designated IGSF1 among the newly identified diagnostic biomarkers emerging from their screening.

Subject of Research: Bioinformatics identification of differentially expressed genes and diagnostic hub genes in gestational diabetes mellitus

Article Title: Bioinformatics analysis of next generation sequencing data to diagnose crucial and novel genes in gestational diabetes mellitus

Article References: Alur, V., Vastrad, B., Raju, V., Vastrad, C., & Kotturshetti, S. (2025). Bioinformatics analysis of next generation sequencing data to diagnose crucial and novel genes in gestational diabetes mellitus. Discover Endocrinology and Metabolism, 1(1), Article 3. https://doi.org/10.1007/s44417-025-00003-2

Image Credits: AI Generated

DOI: 10.1007/s44417-025-00003-2

Keywords: gestational diabetes mellitus, bioinformatics analysis, next-generation sequencing, differentially expressed genes, hub genes, cord blood, Gene Expression Omnibus, DESeq2, protein-protein interaction network, microRNA regulatory network, transcription factors, ROC curve analysis, TRIM54, ELAVL2, PTN, KIT, BMPR1B, SRC

News Source: Juliet Wilcox. (November 16, 2026). Bioinformatics Analysis Identifies Ten Key Hub Genes in Gestational Diabetes. Scienmag.

Tags: bioinformatics analysisBMPR1Bcord bloodDESeq2differentially expressed genesELAVL2Gene Expression Omnibusgestational diabetes mellitushub genesKITmicroRNA regulatory networknext-generation sequencingprotein-protein interaction networkPTNROC curve analysisSRCtranscription factorsTRIM54
Share12Tweet7Share2ShareShareShare1

Related Posts

Investigational Drug IACS-6274 Shows Activity in Advanced Ovarian Cancer Clinical Trial

Investigational Drug IACS-6274 Shows Activity in Advanced Ovarian Cancer Clinical Trial

November 20, 2026
Seasonal Community Vaccination with R21 Cuts Malaria Infection Odds Up to 70%

Seasonal Community Vaccination with R21 Cuts Malaria Infection Odds Up to 70%

November 20, 2026

Lockdown Orders Linked to Healthier Habits Among Digital Weight Management Users

November 20, 2026

Advanced Echocardiography Expands Diagnostic and Management Roles in Hypertrophic Cardiomyopathy

November 20, 2026

POPULAR NEWS

  • Study Uncovers Stark Regional and Social Disparities in Mozambique HIV Testing

    Study Uncovers Stark Regional and Social Disparities in Mozambique HIV Testing

    29 shares
    Share 12 Tweet 7
  • Optimized Machine Learning Predicts Sugarcane Bagasse Ash Concrete Compressive Strength Accurately

    29 shares
    Share 12 Tweet 7
  • Stowers Institute Appoints Brandon Mayer as Chief Technology Officer

    29 shares
    Share 12 Tweet 7
  • Activating MAC-1 Receptors Alleviates Brain Inflammation Following Intracerebral Hemorrhage in Preclinical Models

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Lynch Syndrome Screening Matched Guidelines in Fewer Than Half of Patients

Investigational Drug IACS-6274 Shows Activity in Advanced Ovarian Cancer Clinical Trial

Nanostructured Material Designs Drive Performance Advances in Batteries and Supercapacitors

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.